Formulations of drugs and crystalline side chain polymers to provide controlled and/or sustained release drug formulations.
대표청구항▼
1. A pharmaceutical formulation which (a) comprises (i) a side-chain crystalline (CYSC) polymer which has a polymer backbone and (ii) a single drug, the drug being associated with the CYSC polymer, (b) is free from oil, and (c) is in a dosage form which can be administered by ingestion, injection, s
1. A pharmaceutical formulation which (a) comprises (i) a side-chain crystalline (CYSC) polymer which has a polymer backbone and (ii) a single drug, the drug being associated with the CYSC polymer, (b) is free from oil, and (c) is in a dosage form which can be administered by ingestion, injection, subcutaneous implantation, intramuscular administration, intrathecal administration or inhalation, wherein the CYSC polymer, (A) comprises a plurality of moieties which (a) have the formula -b-Cyand(b) are present (i) as a part of a repeating unit which provides at least part of the polymeric backbone of the polymer, or (ii) as part of a terminal unit of the polymer backbone, or (iii) as both (i) and (ii), the repeating units having formula (1) below, and the terminal units having formula (2) below wherein formula (1), Ych is a moiety forming part of the backbone of the CYSC polymer,in formula (2), Yterm is a moiety at the end of the backbone of the CYSC polymer,and in formula (1) and in formula (2), b is a bond or a moiety which (i) links the Cy moiety to the polymer backbone and (ii) is not an anhydride linkage, andCy is a moiety which (i) comprises 6 to 50 substantially linear carbon atoms, and (ii) associates with other moieties to provide the CYSC polymer with crystallinity;(B) comprises a plurality of repeating units of the formula where Z is a moiety which forms part of the polymer backbone, and Rz is a moiety which (i) is not a -b-Cy moiety, and (ii) is a nitrogen-containing side chain, an oxygen-containing side chain, a fluorine-containing side chain, a phosphorus-containing side chain, a silicon-containing side chain or a ligand group which binds to target receptor sites; the percentage by weight of the repeating units of formula being less than 50%;(C) has a crystalline melting temperature, Tp, of 22 to 70° C., and an onset of melting point, To, such that (Tp−To) is less than 15° C.;(D) has a heat of fusion of least 5 J/g which results from the association of the Cy moieties;(E) is not cross-linked, and(F) has a number average molecular weight, Mn, of 1000 to 20,000 Daltons. 2. A pharmaceutical formulation according to claim 1 wherein at least some of the Cy moieties are present in repeating units having the formula where R is hydrogen or methyl. 3. A pharmaceutical formulation according to claim 2 wherein b is a moiety having the formula 4. A pharmaceutical formulation according to claim 1 wherein at least some of the Cy moieties comprise 12 to 50 substantially linear carbon atoms. 5. A pharmaceutical formulation according to claim 1 wherein at least some of the Cy moieties comprise 18 linear carbon atoms. 6. A pharmaceutical formulation according to claim 1 wherein the repeating units of the formula have the formula where R is hydrogen or methyl. 7. A pharmaceutical formulation according to claim 1 wherein the drug is a neurotransmitter agonist or antagonist. 8. A pharmaceutical formulation according to claim 1 wherein the drug is an antipsychotic. 9. A pharmaceutical formulation according to claim 1 wherein the drug is RISPERIDONE or a pharmacologically active metabolite thereof. 10. A pharmaceutical formulation according to claim 1 wherein the CYSC polymer is a copolymer comprising units derived from octadecyl acrylate (C18A) and acrylic acid (AA), and the drug is a neurotransmitter agonist or antagonist. 11. A pharmaceutical formulation according to claim 10 wherein the drug is RISPERIDONE. 12. A pharmaceutical formulation according to claim 1 wherein the CYSC polymer is a polyacrylate or polymethacrylate. 13. A pharmaceutical formulation according to claim 1 wherein the CYSC polymer is a polyester or a polycarbonate. 14. A pharmaceutical formulation according to claim 1 wherein the CYSC polymer has a number average molecular weight less than 10,000 Daltons. 15. A pharmaceutical formulation according to claim 1 wherein the CYSC polymer is a block copolymer. 16. A pharmaceutical formulation according to claim 1 which contains a first CYSC polymer having a first melting point Tp1 and a second CYSC polymer having a second melting point Tp2 which is at least 2° C. different from Tp1. 17. A pharmaceutical formulation according to claim 1(A) which contains a compound which (i) contains Cy moieties, and (ii) is not a CYSC polymer, and(B) in which the Cy moieties in the CYSC polymer and the Cy moieties in the compound which is not a CYSC polymer together form crystalline aggregates. 18. A pharmaceutical formulation according to claim 1 wherein at least some of the Cy moieties are present in the terminal units and comprise 12-50 substantially linear carbon atoms. 19. A pharmaceutical formulation according to claim 1 wherein at least some of the Cy moieties are present in the terminal units and comprise 18-22 substantially linear carbon atoms. 20. A pharmaceutical formulation according to claim 1 wherein at least some of the Cy moieties are present in the terminal units and comprise 18 substantially linear carbon atoms. 21. A pharmaceutical formulation according to claim 1 wherein at least some of the Cy moieties contain a polyoxyalkylene moiety. 22. A pharmaceutical formulation according to claim 1 wherein at least some of the Rz moieties contain a carboxyl group, or a hydroxyl group. 23. A pharmaceutical formulation according to claim 1 wherein the CYSC polymer is a graft copolymer which comprises a backbone which comprises one or more —Z(Rz)- moieties, and grafted side chains each of which comprises one or more —Y(Rc)- moieties. 24. A pharmaceutical formulation according to claim 1 wherein the drug is associated with the CYSC polymer through chemical bonds. 25. A pharmaceutical formulation according to claim 1 wherein the drug is an antipsychotic drug. 26. A pharmaceutical formulation according to claim 1 wherein the drug is RISPERIDONE or a pharmacologically active metabolite thereof. 27. A pharmaceutical formulation according to claim 1 which contains at least 5% by weight of the drug and which, when tested in vitro (elution into 1 L PBS, pH 7.2 at 37° C., stirred at 100 rpm), releases the drug in a way which has one or more of the following characteristics: (a) an average rate of release no greater than 50 milligrams per day averaged over any 24 hour period during the first 168 hours of elution;(b) an average rate no greater than 25 milligrams per day averaged over any 24 hour period during a period from 12 hours to 168 hours following inception of elution;(c) continuously releases between 1 milligram and 60 milligram of the drug per day over a period of at least 30 days;(d) continuously releases between 1 milligram and 60 milligrams of the drug per day averaged over any 24 hour period during a period from 12 hours to 168 hours following inception of elution;(e) releases no more than 10% by weight of the drug present in the formulation over a period of 24 hours; and,(f) continuously releases a therapeutic dose of drug over a period of at least 30 days wherein the average 24 hour drug release rate is within one standard deviation of the 30 day mean. 28. A pharmaceutical formulation which (a) is in a dosage form which can be administered by ingestion, injection, subcutaneous implantation, intramuscular administration, intrathecal administration or inhalation, and (b) comprises (i) a side-chain crystalline (CYSC) polymer which has a polymer backbone and (ii) a single drug which is associated with the CYSC polymer, wherein the CYSC polymer, (A) comprises a plurality of moieties which (a) have the formula -b-Cyand(b) are present (i) as a part of a repeating unit which provides at least part of the polymeric backbone of the polymer, or (ii) as part of a terminal unit of the polymer backbone, or (iii) as both (i) and (ii), the repeating units having formula (1) below, and the terminal units having formula (2) below wherein formula (1), Ych is a moiety forming part of the backbone of the CYSC polymer,in formula (2), Yterm is a moiety at the end of the backbone of the CYSC polymer,and in formula (1) and in formula (2), b is a bond or a moiety which (i) links the Cy moiety to the polymer backbone and (ii) is not an anhydride linkage, andCy is a moiety which (i) comprises 6 to 50 substantially linear carbon atoms, and (ii) associates with other moieties to provide the CYSC polymer with crystallinity;the polymer backbone consisting essentially of repeating units having the formula (1)(B) has a crystalline melting temperature, Tp, of 22 to 70° C., and an onset of melting point, To, such that (Tp−To) is less than 15° C.;(C) has a heat of fusion of least 5 J/g which results from the association of the Cy moieties; and(D) is not cross-linked. 29. A pharmaceutical formulation according to claim 28 wherein the CYSC polymer has a number average molecular weight, Mn, of 1,000 to 20,000 Daltons. 30. A pharmaceutical formulation according to claim 28 wherein the CYSC polymer has a number average molecular weight, Mn, of less than 10,000 Daltons. 31. A pharmaceutical formulation according to claim 28 wherein the CYSC polymer is a polyacrylate or polymethacrylate. 32. A pharmaceutical formulation according to claim 28 wherein the CYSC polymer is a polyester. 33. A pharmaceutical formulation according to claim 28 wherein the CYSC polymer is a polycarbonate. 34. A pharmaceutical formulation according to claim 1 wherein the CYSC polymer is a block copolymer. 35. A pharmaceutical formulation according to claim 1 which contains a first CYSC polymer having a first melting point Tp1 and a second CYSC polymer having a second melting point Tp2 which is at least 2° C. different from Tp1. 36. A pharmaceutical formulation according to claim 26(A) which contains a compound which (i) contains Cy moieties, and (ii) is not a CYSC polymer, and(B) in which the Cy moieties in the CYSC polymer and the Cy moieties in the compound which is not a CYSC polymer together form crystalline aggregates. 37. A pharmaceutical formulation according to claim 1 wherein at least some of the Cy moieties comprise 12-50 substantially linear carbon atoms. 38. A pharmaceutical formulation according to claim 1 wherein at least some of the Cy moieties comprise 18-22 substantially linear carbon atoms. 39. A pharmaceutical formulation according to claim 1 for use in therapy or diagnosis. 40. A method of making a pharmaceutical formulation as claimed in claim 1 which comprises melting the CYSC polymer, mixing the drug with the molten polymer in the absence of solvents, and cooling the mixture to below its melting point to cause crystallization and solidification of the formulation. 41. A pharmaceutical formulation according to claim 1 which is in a dosage form selected from liquids, tablets, pills and capsules. 42. A pharmaceutical formulation according to claim 28 which is in a dosage form selected from liquids, tablets, pills and capsules. 43. A pharmaceutical formulation according to claim 1 wherein the percentage by weight of the repeating units of the formula is 5-25%. 44. A pharmaceutical formulation according to claim 1 wherein the percentage by weight of the repeating units of the formula is less than 23%. 45. A pharmaceutical formulation according to claim 1 wherein, in each of the repeating units of formula (1), b is not an amide linkage, and the percentage by weight of the repeating units of the formula is 5-25%. 46. A pharmaceutical formulation according to claim 1 wherein, in each of the repeating units of formula (1), the b moiety is selected from the group consisting of ester, carbonyl, amine oxide, hydrocarbon, amino, ether, polyoxyalkylene and ionic salt linkages, and the percentage by weight of the repeating units of the formula is 5-25%. 47. A pharmaceutical formulation according to claim 1 wherein, in each of the repeating units of formula (1), the b moiety is an ester linkage, and the percentage by weight of the repeating units of the formula is 5-25%. 48. A pharmaceutical formulation according to claim 1 wherein, in each of the repeating units of formula (1), the b moiety is a moiety selected from one or more of carbonyl, amine oxide, amino, polyoxyalkylene and ionic salt linkages. 49. A pharmaceutical formulation according to claim 1 wherein in each of the repeating units of the formula Rz is a moiety selected from one or more of a nitrogen-containing side chain, a fluorine-containing side chain, a phosphorus-containing side chain, a silicone-containing side chain and a ligand group which binds to target receptor sites. 50. A pharmaceutical formulation which (a) comprises (i) a side-chain crystalline (CYSC) polymer which has a polymer backbone, (ii) hyaluronic acid, and (ii), in addition to the hyaluronic acid, a single other drug which is associated with the CYSC polymer,(b) is free from oil, and(c) is in a dosage form which can be administered by ingestion, injection, subcutaneous implantation, intramuscular administration, intrathecal administration or inhalation, wherein the CYSC polymer, (A) comprises a plurality of moieties which (a) have the formula -b-Cyand(b) are present (i) as a part of a repeating unit which provides at least part of the polymeric backbone of the polymer, or (ii) as part of a terminal unit of the polymer backbone, or (iii) as both (i) and (ii), the repeating units having formula (1) below, and the terminal units having formula (2) below wherein formula (1), Ych is a moiety forming part of the backbone of the CYSC polymer,in formula (2), Yterm is a moiety at the end of the backbone of the CYSC polymer,and in formula (1) and in formula (2), b is a bond or a moiety which (i) links the Cy moiety to the polymer backbone and (ii) is not an anhydride linkage, andCy is a moiety which (i) comprises 6 to 50 substantially linear carbon atoms, and (ii) associates with other moieties to provide the CYSC polymer with crystallinity;(B) comprises a plurality of repeating units of the formula where Z is a moiety which forms part of the polymer backbone, and Rz is a moiety which (i) is not a -b-Cy moiety, and (ii) is a nitrogen-containing side chain, an oxygen-containing side chain, a fluorine-containing side chain, a phosphorus-containing side chain, a silicon-containing side chain or a ligand group which binds to target receptor sites; the percentage by weight of the repeating units of formula being less than 50%;(C) has a crystalline melting temperature, Tp, of 22 to 70° C., and an onset of melting point, To, such that (Tp−To) is less than 15° C.;(D) has a heat of fusion of least 5 J/g which results from the association of the Cy moieties;(E) is not cross-linked, and(F) has a number average molecular weight, Mn, of 1000 to 20,000 Daltons. 51. A pharmaceutical formulation according to claim 50 wherein the percentage by weight of the repeating units of the formula is 5-25%. 52. A pharmaceutical formulation according to claim 50 wherein the percentage by weight of the repeating units of the formula is less than 23%. 53. A pharmaceutical formulation according to claim 50 wherein, in each of the repeating units of formula (1), b is not an amide linkage, and the percentage by weight of the repeating units of the formula is 5-25%. 54. A pharmaceutical formulation according to claim 50 wherein, in each of the repeating units of formula (1), the b moiety is selected from the group consisting of ester, carbonyl, amine oxide, hydrocarbon, amino, ether, polyoxyalkylene and ionic salt linkages, and the percentage by weight of the repeating units of the formula is 5-25%. 55. A pharmaceutical formulation according to claim 50 wherein, in each of the repeating units of formula (1), the b moiety is an ester linkage, and the percentage by weight of the repeating units of the formula is 5-25%. 56. A pharmaceutical formulation according to claim 50 wherein, in each of the repeating units of formula (1), the b moiety is a moiety selected from one or more of carbonyl, amine oxide, amino, polyoxyalkylene and ionic salt linkages. 57. A pharmaceutical formulation according to claim 50 wherein, in each of the repeating units of the formula Rz is a moiety selected from one or more of a nitrogen-containing side chain, a fluorine-containing side chain, a phosphorus-containing side chain, a silicone-containing side chain and a ligand group which binds to target receptor sites. 58. A pharmaceutical formulation according to claim 28 which contains, in addition to the single drug, hyaluronic acid.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (64)
Nathan, Aruna, Alkyd-lactone copolymers for medical applications.
Fischer Bernhard (Leonberg DEX) Zoll Martin (Gechingen DEX) Wender Joachim (Leonberg DEX) Rochlitzer Frank (Altdorf DEX), Device for continuously detecting blood parameters.
Stewart Ray F. (Redwood City CA) Greene Lawrence C. (Boulder Creek CA) Bhaskar Ravi K. (Lawrence KS), Microcapsule having temperature-dependent permeability profile.
Randolph Theodore W. ; Lengsfeld Corinne ; Falk ; III Richard Frank, Microparticles of lactide-co-glycolide copolymers and methods of making and using the same.
Coombes Allan Gerald Arthur,GBX ; Davis Stanley Stewart,GBX ; Major Diane Lisa,GBX ; Wood John Michael,GBX, Polymeric lamellar substrate particles for drug delivery.
Rickey Michael E. ; Ramstack J. Michael ; Lewis Danny H. ; Mesens Jean,BEX, Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent.
Schmitt Edward E. (Palo Alto CA) Clarke Raymond (Los Altos CA) Larson Andrew W. (Palo Alto CA) Bitler Steven P. (Menlo Park CA) Tsugita Ross S. (Mountain View CA) Schultz Donald A. (San Mateo CA), Pressure-sensitive adhesives.
Plate Nicolai A.,RUX ; Valuev Lev I.,RUX ; Uzhinova Lubov D.,RUX ; Sinani Vladimir A.,RUX, Process for preparing biologically compatible polymers and their use in medical devices.
Bitler Steven P. (Menlo Park CA) Stewart Ray F. (Redwood City CA) Kamp David A. (Sunnyvale CA) Freelin Robert G. (McLean VA) Yoon Valentine Y. (Redwood City CA), Thermoplastic Elastomers.
Helmut Meffert DE; Axel Sanner DE; Gunther Berndl DE; Folker Ruchatz DE; Karl Kolter DE; Kurt Heinz Bauer DE, Use of copolymers of monoethylenically unsaturated carboxylic acids as solubilizers.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.